Compare IDEXX Laboratories, Inc. (IDXX) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Jabil Inc — how do they compare? IDEXX Laboratories, Inc. trades at $573.07 (market cap $46.22B), while Jabil Inc trades at $368.53 (market cap $37.37B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Jabil Inc pays a 0.09% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | JBL | |
|---|---|---|
Market Cap | $46.22B | $37.37B |
Sector | Health | Technology |
52-Week High | $766.68 | $385.50 |
52-Week Low | $526.44 | $192.49 |
Enterprise Value | $47.12B | $39.90B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
JBL trades at $368.37, up 9.43% with strong bullish momentum driven by AI infrastructure demand and recent earnings beats. The stock shows robust technical strength with moving averages signaling buy and price approaching resistance at $371. Fundamentally, revenue growth accelerated to $33.6B in 2026 with net profit margin improving to 2.56%, though valuation multiples remain elevated with P/E at 44.63.
Outlook remains positive with analyst consensus target of $448.29 (22% upside) and 50% buy ratings. Key opportunities include projected AI revenue growth to $20B+ by 2027, while risks include competitive pressures and the stock's premium valuation. Recent UBS upgrade to Buy highlights multi-year AI growth cycle potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
